Anti-NCL-MycG4/G-quadruplex complex Antibody (NG14) from ProteoGenix; catalogue ARO-A22654; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The Anti-NCL-MycG4/G-quadruplex complex Antibody (NG14) is a highly specific and potent antibody designed for the detection and inhibition of the NCL-MycG4/G-quadruplex complex. This complex is a crucial component in the regulation of gene expression and has been implicated in various cellular processes, including cancer development and progression.
With its unique specificity and high affinity for the NCL-MycG4/G-quadruplex complex, NG14 is an essential tool for researchers studying the role of this complex in cancer biology. This antibody is validated for use in a variety of applications, making it a versatile and reliable choice for your research needs.
One of the main applications of NG14 is its use in immunofluorescence assays, where it can be used to visualize the localization and distribution of the NCL-MycG4/G-quadruplex complex within cells. This allows for a better understanding of the complex’s function and its potential role in cancer development.
NG14 can also be used in chromatin immunoprecipitation (ChIP) assays to investigate the binding of the NCL-MycG4/G-quadruplex complex to specific DNA sequences. This is particularly useful in identifying potential target genes regulated by this complex, providing insights into its role in cancer progression.
Moreover, NG14 has been shown to effectively inhibit the NCL-MycG4/G-quadruplex complex, making it a valuable tool for functional studies. By blocking the complex’s activity, researchers can observe the downstream effects on gene expression and cellular processes, further elucidating its role in cancer biology.
In addition to these applications, NG14 has been successfully used in various experimental models, including cell lines, tissue samples, and animal models. Its reliability and reproducibility make it a trusted choice for researchers in the field of cancer biology.
In summary, the Anti-NCL-MycG4/G-quadruplex complex Antibody (NG14) is a highly specific and potent tool for targeting the NCL-MycG4/G-quadruplex complex. Its applications in immunofluorescence, ChIP assays, and functional studies make it an essential asset for cancer research. Trust NG14 to provide accurate and reliable results for your research needs. Order now and take your cancer research to the next level.
ProteoGenix catalogue number ARO-A22654. For research use only.
Target: NCL-MycG4 complex; Clonality: Monoclonal Antibody; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| NCL-MycG4 complex |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
